REIMAGINE: A prospective real-world evaluation of clinical remission in patients with severe asthma treated with mepolizumab in a timely manner
Bibliographic record
Abstract
Background: Clinical remission (CR) in severe asthma (SA) is an ambitious and achievable treatment goal; further prospective real-world analyses are needed to determine the impact of timely intervention on achieving CR. Aims: REIMAGINE prospectively evaluates the proportion of a subset of patients with SA with an eosinophilic phenotype (EP) achieving CR with mepolizumab and clinical characteristics influencing CR status. Methods: This global, prospective, real-world, 2-year study enrolled adult patients with SA-EP newly prescribed mepolizumab. Inclusion criteria: predicted FEV1 ≥60%, ≤4 exacerbations/year, no maintenance systemic corticosteroid use. Primary outcome: proportion of patients achieving CR. Here we report interim baseline data. Results: As of 20/2/2025, 177 patients were enrolled (Table). Mean (SD) asthma duration was 38.4 (23.1) years; exacerbation rate in the year before mepolizumab was 1.7 (0.9) as of 25/2/2025. Comorbidities included allergic rhinitis (37.9%) and nasal polyps (14.7%). The mean (SD) Asthma Control Test score was 14.8 (4.6) indicating poorly controlled asthma. Quality of life assessments reflected moderate impairment. Conclusions: This study will inform on CR outcomes when mepolizumab is introduced earlier in the SA disease progression, as shown by better baseline lung function than traditionally reported in RCTs. Funding: GSK (219871). erj;66/suppl_69/PA4626/F1 F1 F1
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.004 | 0.004 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".